Literature DB >> 20299060

Percutaneous radio frequency ablation of renal tumors in patients with von Hippel-Lindau disease: preliminary results.

Byung Kwan Park1, Chan Kyo Kim.   

Abstract

PURPOSE: We investigated the preliminary results of percutaneous radio frequency ablation for renal tumors in patients with von Hippel-Lindau disease.
MATERIALS AND METHODS: Between October 2005 and April 2009 image guided radio frequency ablation was performed to ablate a total of 48 renal tumors in 11 patients with von Hippel-Lindau disease. Six of the 11 patients had undergone radical or partial nephrectomy for renal cell carcinomas. We recorded whether tumors were successfully ablated, major complications, and changes in serum creatinine and the estimated glomerular filtration rate.
RESULTS: A total of 29 sessions (70 ablations) were done. Of 48 tumors 42 (88%) were successfully ablated at 1 (41) or 3 (1) sessions and 6 (12%) had residual or recurrent lesions. Two residual tumors were treated with nephrectomy, 2 were too small to be ablated and 1 was treated with chemotherapy due to pulmonary metastasis. The remaining residual tumor was completely ablated at 2 sessions but recurred. Overall 8 of 11 patients (73%) were successfully treated with radio frequency ablation but 3 (27%) had residual or recurrent tumors. Two major complications (6.9%) developed at a total of 29 sessions, including arteriovenous fistula and ureteral perforation. Mean serum creatinine increased 11.2% and the mean estimated glomerular filtration rate decreased 9.4% after the last ablation.
CONCLUSIONS: Percutaneous radio frequency ablation may be a treatment option for multifocal renal tumors in patients with von Hippel-Lindau disease but preliminary results were not satisfactory due to technical failure. 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20299060     DOI: 10.1016/j.juro.2010.01.022

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Salvage Surgery After Percutaneous Ablation of Renal Mass in Solitary Kidney in a Patient With Von Hippel-Lindau.

Authors:  Patrick T Gomella; W Marston Linehan; Mark W Ball
Journal:  Clin Genitourin Cancer       Date:  2019-01-26       Impact factor: 2.872

2.  Management of renal tumors in Von Hippel-Lindau disease by percutaneous CT fluoroscopic guided radiofrequency ablation: preliminary results.

Authors:  Yoichi Iwamoto; Hideki Kanda; Koichiro Yamakado; Norihito Soga; Kiminobu Arima; Kan Takeda; Yoshiki Sugimura
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

3.  Invasive management of renal cell carcinoma in von Hippel-Lindau disease.

Authors:  Diego M Carrion; Estefanía Linares-Espinós; Emilio Ríos González; Alfredo Aguilera Bazán; Mario Alvarez-Maestro; Luis Martinez-Pineiro
Journal:  Cent European J Urol       Date:  2020-05-20

Review 4.  Renal cancer in von Hippel-Lindau disease and related syndromes.

Authors:  Birke Bausch; Cordula Jilg; Sven Gläsker; Alexander Vortmeyer; Niklas Lützen; Alexandra Anton; Charis Eng; Hartmut P H Neumann
Journal:  Nat Rev Nephrol       Date:  2013-07-30       Impact factor: 28.314

5.  CT-Guided Radiofrequency Ablation of T1a Renal Cell Carcinoma in Korea: Mid-Term Outcomes.

Authors:  Hae Jin Kim; Byung Kwan Park; Jung Jae Park; Chan Kyo Kim
Journal:  Korean J Radiol       Date:  2016-08-23       Impact factor: 3.500

6.  Implications of Von Hippel-Lindau Syndrome and Renal Cell Carcinoma.

Authors:  Kenan Ashouri; Sophia Mohseni; John Tourtelot; Pranav Sharma; Philippe E Spiess
Journal:  J Kidney Cancer VHL       Date:  2015-09-25

7.  Repeat Percutaneous Radiofrequency Ablation of T1 Renal Cell Carcinomas is Safe in Patients with Von Hippel-Lindau Disease.

Authors:  Joel Wessendorf; Alexander König; Hendrik Heers; Andreas H Mahnken
Journal:  Cardiovasc Intervent Radiol       Date:  2021-08-19       Impact factor: 2.740

Review 8.  Asian Conference on Tumor Ablation guidelines for renal cell carcinoma.

Authors:  Byung Kwan Park; Shu Huei Shen; Masashi Fujimori; Yi Wang
Journal:  Investig Clin Urol       Date:  2021-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.